title: Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
abstract: Stroke is a leading cause of cardiovascular morbidity and mortality worldwide. Approximately, 795,000 strokes occur in the USA each year, 610,000 of which are first events, and 185,000 of which are recurrent events. Of all strokes, 87% are ischemic strokes. Novel anticoagulants serve as an alternative antithrombotic intervention in patients with ischemic cerebrovascular disease. This paper reviews the role of the novel anticoagulants, dabigatran, rivaroxaban and apixaban, in stroke prevention among patients with nonvalvular atrial fibrillation.
authors.affiliation: Department of Neurology, Stroke Program, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153, USA. smoralesvidal@lumc.edu
authors.forename: Sarkis
authors.initials: S
authors.lastname: Morales-Vidal
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Schneck
authors.forename: Murray
authors.initials: M
authors.lastname: Flaster
authors.forename: José
authors.initials: J
authors.lastname: Biller
mesh_terms: D000991:Antithrombins / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications* / Q000188:drug therapy; D001562:Benzimidazoles / Q000627:therapeutic use*; D000069604:Dabigatran; D065427:Factor Xa Inhibitors; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011728:Pyridones / Q000627:therapeutic use*; D000069552:Rivaroxaban; D020521:Stroke / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D013876:Thiophenes / Q000627:therapeutic use*; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000991:Antithrombins; D001562:Benzimidazoles; D065427:Factor Xa Inhibitors; D009025:Morpholines; D011720:Pyrazoles; D011728:Pyridones; D013876:Thiophenes; D015091:beta-Alanine; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran